MORRISVILLE, N.C. — Sicel Technologies has signed on two cancer centers in Florida as the first commercial users of their implantable radiation sensor technology.
Boca Raton Community Hospital’s Lynn Cancer Institute and Melbourne Internal Medical Associates will use Sicel’s Dose Verification System as part of their treatment programs. The system includes an implantable radiation sensor and a hand-held reader to measure the dose of radiation delivered to a tumor and surrounding tissue.
Sicel recently closed on $12 million in new financing. The company, which was founded in 1999, now employs 31 people.
“Radiation oncologists will now know with certainty that a patient is receiving the correct dose of radiation,” said Tim Williams, chair of the radiation oncology department at Lynn Regional Cancer Center. “This is just one example of our hospital’s commitment to staying on the edge of technology and investing in what is best for the patient.”
The Food and Drug Administration recently approved the DVS for use in breast cancer and prostate cancer victims. Shortly after winning the FDA approvals, Sicel closed on the additional financing.
“Both Lynn Cancer Institute and MIMA have a history of providing the best care for their cancer patients by being among the first centers to adopt cutting edge technologies,” said Michael Riddle, Sicel’s chief technology officer. “We are extremely pleased to have two such prestigious institutions as our first users in the United States.”
Sicel utilizes technology licensed from North Carolina State University.